How disruption of cell cycle regulating genes might predispose to sun-induced skin cancer

Cell Cycle

Volumn 4, Issue 5, 2005, Pages 643-645

  Rünger, Thomas M ^a   Vergilis, Irene ^a   Sarkar, Papri ^a,b   DePinho, Ronald A ^c   Sharpless, Norman E ^d  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

CDKN2; DNA photoproducts; DNA repair; Melanoma; p16INK4a; p19ARF; Skin cancer; Ultraviolet light

Indexed keywords

ARF PROTEIN; PROTEIN P16INK4A; PROTEIN P19; PROTEIN P53; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN;

CANCER INHIBITION; CANCER SUSCEPTIBILITY; CELL CYCLE; CELL DISRUPTION; CELL REGENERATION; DNA DAMAGE; DNA REPAIR; EXCISION REPAIR; GENE CONTROL; GENE LOCUS; GENETIC CODE; GERM LINE; KERATINOCYTE; MELANOCYTE; MELANOMA; MUTATION; MUTATOR GENE; NONHUMAN; PHENOTYPE; POINT MUTATION; REGULATORY MECHANISM; SHORT SURVEY; SKIN CANCER; ULTRAVIOLET IRRADIATION; ULTRAVIOLET RADIATION;

EID: 25144477026     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.4.5.1673     Document Type: Short Survey

References (40)

1. Sharpless E, Chin L. The INK4a/ARF locus and melanoma. Oncogene 2003; 22:3092-8.
2. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366:704-7.
3. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92:725-34.
4. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 1998; 95:8292-7.
5. Stott FJ, Bates S, James MC, McConnel BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, Peters G. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998; 17:5001-14.
6. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998; 92:713-23.
7. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004; 432:316-23.
8. Chin L, Merlino G, DePinho RA. Malignant melanoma: Modern black plague and genetic black box. Genes Develop 1998; 12:3467-81.
9. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark WH, Jr., Tucker MA, Cracopoli NC. Germline p16 mutations in familial melanoma. Nat Genet 1994; 8:15-21.
10. FitzGerald MG, Harkin DP, Silva-Arrieta S, MacDonald DJ, Lucchina LC, Unsal H, O'Neill E, Koh J, Finkelstein DM, Isselbacher KJ, Sober AJ, Haber DA. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: Analysis of a clinic-based population. Proc Natl Acad Sci USA 1996; 93:8541-5.
11. Haluska FG, Hodi FS. Molecular genetics of familial cutaneous melanoma. J Clin Oncol 1998; 16:670-82.
12. Kannan K, Sharpless NE, Xu J, O'Hagan RC, Bosenberg M, Chin L. Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model. Proc Natl Acad Sci USA 2003; 100:1221-5.
13. Ruas M, Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim 1998; 1378:115-77.
14. ARF. J Natl Cancer Inst 2005; 96:1790-3.
15. Giannattasio M, Lazzaro F, Longhese MP, Plevani P, Muzi-Falconi M. Physical and functional interactions between nucleotide excision repair and DNA damage checkpoint. EMBO J 2004; 23:429-38.
16. Stucki M, Stagljar I, Jonsson ZO, Hubscher U. A coordinated interplay: Proteins with multiple functions in DNA replication, DNA repair, cell cycle/checkpoint control, and transcription. Prog Nucl Acid Res Mol Biol 2001; 65:261-98.
17. Ferguson DO, Sekiguchi JM, Frank KM, Gao Y, Charpless NE, Gu Y, Manis J, DePinho RA, Alt FW. The interplay between nonhomologous end-joining and cell cycle checkpoint factors in development, genomic stability, and tumorigenesis. Cold Spring Harb Symp Quant Biol 2000; 65:395-403.
18. Decraene D, Agostinis P, Pupe A, de Haes P, Garmyn M. Acute response of human skin to solar radiation: Regulation and function of the p53 protein. J Photochem Photobiol B 2001; 63:78-83.
19. Smith ML, Seo YR. p53 regulation of DNA excision repair pathways. Mutagenesis 2002; 17:149-56.
20. Adimoolam S, Ford JM. p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene. Proc Natl Acad Sci USA 2002; 99:12985-90.
21. Wei Q, Lee JE, Gershenwald JE, Ross MI, Mansfield PF, Strom SS, Wang LE, Guo Z, Qiao Y, Amos CI, SPitz MR, Duvic M. Repair of UV light-induced DNA damage and risk of cutaneous malignant melanoma. J Natl Cancer Inst 2003; 95:308-15.
22. Kraemer KH, Lee MM, Scotto J. Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases. Arch Dermatol 1987; 123:241-50.
23. Kraemer KH, Lee MM, Andrews AD, Lambert WC. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. The xeroderma pigmentosum paradigm. Arch Dermatol 1994; 130:1018-21.
24. Baccarelli A, Calista D, Minghetti P, Marinelli B, Albetti B, Tseng T, Heayati M, Grossman L, Landi G, Struewing JP, Landi MT. XPD gene polymorphism an host characteristics in the accociation with cutaneous malignant melanoma risk. Br J Cancer 2004; 90:497-502.
25. Seetharam S, Waters HL, Seidman MM, Kraemer KH. Ultraviolet mutagenesis in a plasmid vector replicated in lymphoid cells from patient with the melanoma-prone disorder dysplastic nevus syndrome. Cancer Res 1989; 49:5918-21.
26. Moriwaki SI, Tarone RE, Tucker MA, Goldstein AM, Kraemer KH. Hypermutability of UV-treated plasmids in dysplastic nevus/familial melanoma cell lines. Cancer Res 1997; 57:4637-41.
27. Kraemer KH. NRAS hypermutability in familial melanoma with CDKN2A mutations - cause and effect? J Natl Cancer Inst 2003; 95:768-9.
28. Sharpless NE, Alson S, Chan S, Silver DP, Castrillon DH, DePinho RA. p16(INK4a) and p53 deficiency cooperate in tumorigenesis. Cancer Res 2002; 62:2761-5.
29. Rünger TM, Möller K, Jung T, Dekant B. DNA damage formation, DNA repair, and survival after exposure of DNA repair-proficient and nucleotide excision repair-deficient human lymphoblasts to UVA1 and UVB. Int J Radiat Biol 2000; 76:789-97.
30. Therrien JP, Drouin R, Baril C, Drobetsky EA. Human cells compromised for p53 function exhibit defective global and transcription-coupled nucleotide excision repair, whereas cells compromised for pRb function are defective only in global repair. Proc Natl Acad Sci USA 1999; 96:15038-43.
31. Brash DE, Ziegler A, Jonason AS, Simon JA, Kunala S, Leffell DJ. Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor progression. J Invest Dermatol Symp Proc 1996; 1:136-42.
32. Lassam NJ, From L, Kahn HJ. Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res 1993; 53:2235-8.
33. Albino AP, Vidal MJ, McNutt NS, SHea CR, Prieto VG, Nanus DM, Palmer JM, Hayward NK. Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res 1994; 4:35-45.
34. Castresana JS, Rubio MP, Vazquez JJ, et al. Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma. Int J Cancer 1993; 55:562-5.
35. Lubbe J, Reichel M, Burg G, Kleihues P Absence of p53 gene mutations in cutaneous melanoma. J Invest Dermatol 1994; 102:819-21.
36. PappT, Jafari M, Schiffmann D. Lack of p53 mutations and loss of heterozygosity in non-cultured human melanocytic lesions. J Cancer Res Clin Oncol 1996; 122:541-8.
37. Bardeesy N, Bastian BC, Hezel A, Pinkel D, DePinho RA, Chin L. Dual inactivation of RB and p53 pathways in RAS-induced melanomas. Mol Cell Biol 2001; 21:2144-53.
38. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996; 85:27-37.
39. Sharpless NE, Bardeesy N, Lee KH, Carrasco D, Castrillon DH, Aguirre AJ, Wu EA, Horner JW, DePinho RA. Loss of p16INK4a with retention of p19ARF predisposes mice to tumorigenesis. Nature 2001; 413:86-91.
40. Sharpless NE, Ramsey MR, Balasubramanian P, Castrillon DH, DePinho RA. The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis. Oncogene 2004; 23:379-85.